Tao Liu1, Aabha Jain2, Michael Fung3, Christopher Vinnard4, Vijay Ivaturi1. 1. a Center for Translational Medicine, School of Pharmacy , University of Maryland , Baltimore , Maryland , USA. 2. b Department of Medicine , Drexel University College of Medicine , Philadelphia , PA , USA. 3. c Department of Opthalmology, Wills Eye Hospital , SKMC at Thomas Jefferson University , Philadelphia , PA , USA. 4. d Department of Medicine , Public Health Research Institute, New Jersey Medical School , Rutgers, Newark , NJ , USA.
Abstract
PURPOSE: Acute retinal necrosis (ARN) is a feared complication of infectious retinitis most commonly caused by varicella zoster virus (VZV). We performed a pharmacokinetic modeling and simulation study by integrating the existing understanding of physiology with previously published data to evaluate the vitreal penetration of oral valacyclovir for the treatment of ARN, under various dosing scenarios. METHOD: We compared different oral valacyclovir dosing regimens with intravenous acyclovir. The vitreous compartment was modeled as a peripheral compartment, and paired serum and vitreal acyclovir concentrations were obtained from previously published data of adult patients with ARN undergoing vitrectomy. The efficacy threshold for vitreal acyclovir concentrations was based on the previously reported IC50 values for VZV. RESULTS: Based on the minimum vitreal acyclovir concentrations (Cmin) relative to the mean IC50 for VZV, valacyclovir 1.5 g every 8 hours performed similarly to intravenous acyclovir 700 mg every 8 hours, with the minimum concentration (Cmin) exceeding the mean IC50 after the second dose. In contrast, the standard dosing regimen for herpes zoster, valacyclovir 1 g every 8 hours, performed inferiorly to the intravenous acyclovir regimen throughout the dosing interval. CONCLUSIONS: Modeling and simulation data support oral valacyclovir for the treatment of ARN, although the required dosing exceeds the recommended FDA dose size for herpes zoster.
PURPOSE:Acute retinal necrosis (ARN) is a feared complication of infectious retinitis most commonly caused by varicella zoster virus (VZV). We performed a pharmacokinetic modeling and simulation study by integrating the existing understanding of physiology with previously published data to evaluate the vitreal penetration of oral valacyclovir for the treatment of ARN, under various dosing scenarios. METHOD: We compared different oral valacyclovir dosing regimens with intravenous acyclovir. The vitreous compartment was modeled as a peripheral compartment, and paired serum and vitreal acyclovir concentrations were obtained from previously published data of adult patients with ARN undergoing vitrectomy. The efficacy threshold for vitreal acyclovir concentrations was based on the previously reported IC50 values for VZV. RESULTS: Based on the minimum vitreal acyclovir concentrations (Cmin) relative to the mean IC50 for VZV, valacyclovir 1.5 g every 8 hours performed similarly to intravenous acyclovir 700 mg every 8 hours, with the minimum concentration (Cmin) exceeding the mean IC50 after the second dose. In contrast, the standard dosing regimen for herpes zoster, valacyclovir 1 g every 8 hours, performed inferiorly to the intravenous acyclovir regimen throughout the dosing interval. CONCLUSIONS: Modeling and simulation data support oral valacyclovir for the treatment of ARN, although the required dosing exceeds the recommended FDA dose size for herpes zoster.
Authors: Ioannis M Aslanides; Stephen De Souza; David T W Wong; Louis R Giavedoni; Filiberto Altomare; Efstathios T Detorakis; George D Kymionis; Ioannis G Pallikaris Journal: Retina Date: 2002-06 Impact factor: 4.256
Authors: Geoffrey G Emerson; Justine R Smith; David J Wilson; James T Rosenbaum; Christina J Flaxel Journal: Ophthalmology Date: 2006-09-25 Impact factor: 12.079
Authors: Robert William Wong; J Michael Jumper; H Richard McDonald; Robert N Johnson; Arthur Fu; Brandon J Lujan; Emmett T Cunningham Journal: Br J Ophthalmol Date: 2012-12-12 Impact factor: 4.638
Authors: S Weller; M R Blum; M Doucette; T Burnette; D M Cederberg; P de Miranda; M L Smiley Journal: Clin Pharmacol Ther Date: 1993-12 Impact factor: 6.875